Melanoma and Advanced Skin Cancer
Iovance Biotherapeutics Inc. is active in clinical research for melanoma, including previously treated advanced melanoma and untreated advanced melanoma. Its studies also extend to treatment settings where tumor-infiltrating lymphocytes are used alone or alongside immune checkpoint inhibitors.
- Tumor-infiltrating lymphocyte therapy
- Advanced melanoma
- Combination immunotherapy
The sponsor’s melanoma-focused trials include both standalone and combination cell therapy approaches aimed at solid tumor disease control.
Metastatic Non-Small-Cell Lung Cancer and Thoracic Oncology
The company funds research in metastatic non-small-cell lung cancer, with attention to tumor-infiltrating lymphocyte treatment strategies for advanced lung disease. These trials reflect interest in thoracic oncology and immunologically driven approaches for difficult-to-treat tumors.
- Metastatic non-small-cell lung cancer
- Autologous TIL therapy
- Immunotherapy combinations
Research activity in this area centers on lung cancer populations with limited remaining treatment options.
Cervical Carcinoma and Gynecologic Oncology
Iovance supports clinical studies in recurrent, metastatic, or persistent cervical carcinoma, including investigations of LN-145 and related cell-based immunotherapy approaches. This places the sponsor within gynecologic oncology research focused on advanced disease.
- Recurrent cervical carcinoma
- Metastatic cervical carcinoma
- Persistent cervical carcinoma
The cervical cancer portfolio includes interest in both treatment-naive combinations and previously treated patient groups.
Solid Tumors and Cell-Based Immuno-Oncology
The sponsor also funds broader solid tumor research involving LN-144, LN-145, and lifileucel, with a strong emphasis on autologous TIL platforms. These programs span multiple tumor types and reflect a commitment to immuno-oncology in advanced malignancies.
- Solid tumors
- Autologous tumor-infiltrating lymphocytes
- Cell therapy platforms
Across its portfolio, the company’s research interest remains concentrated on advanced cancer settings where immune-based therapies may be applied.
